Golcadomide
- Generic Name
- Golcadomide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30FN5O5
- CAS Number
- 2379572-34-4
- Unique Ingredient Identifier
- 29HLR8Z5BR
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 90
- Registration Number
- NCT06425302
- Locations
- 🇺🇸
Local Institution - 0020, New Brunswick, New Jersey, United States
🇩🇪Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden, Germany
🇮🇹Local Institution - 0179, Rozzano, Milano, Italy
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 36
- Registration Number
- NCT06363630
- Locations
- 🇺🇸
Local Institution - 0002, Atlanta, Georgia, United States
🇺🇸Local Institution - 0001, Lenexa, Kansas, United States
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 850
- Registration Number
- NCT06356129
- Locations
- 🇺🇸
Cancer Care Specialists, Reno, Nevada, United States
🇺🇸Local Institution - 0498, East Brunswick, New Jersey, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 65
- Registration Number
- NCT06271057
- Locations
- 🇫🇷
Hopital Henri Mondor, Créteil, France
🇫🇷Chu Dijon Bourgogne, Dijon, France
🇫🇷Chu de Grenoble, La Tronche, France
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma-RecurrentHigh Grade B-Cell Lymphoma-RecurrentPrimary Mediastinal Large B-Cell Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-RefractoryTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-RecurrentTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-RefractoryDiffuse Large B-Cell Lymphoma-RecurrentFollicular Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-RefractoryFollicular Lymphoma-Refractory
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Nathan Denlinger
- Target Recruit Count
- 18
- Registration Number
- NCT06209619
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
- Conditions
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05788081
- Locations
- 🇦🇺
Grampians Health, Ballarat, Victoria, Australia
🇦🇺Eastern Health, Box Hill, Victoria, Australia
🇦🇺Fiona Stanley Hospital, Perth, Western Australia, Australia
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05169515
- Locations
- 🇺🇸
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program, San Francisco, California, United States
🇮🇹Irccs Ospedale San Raffaele;U.O. Oculistica, Milano, Lombardia, Italy
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.